STRATA Skin Sciences Unveils Promising Acne Treatment Study

STRATA Skin Sciences

HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) recently announced the publication of a clinical study in the Journal of Clinical and Aesthetic Dermatology. Titled “A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating Mild-to-Moderate Acne in Healthy Adolescents and Young Adults,” the study demonstrates the effectiveness of the TheraClear®X Acne Therapy System.

The study was spearheaded by Dr. Glynis Ablon, a board-certified dermatologist with 28 years of experience. Conducted at the Ablon Skin Institute & Research Center, the trial involved 30 participants undergoing six weekly TheraClear®X treatments. The results were noteworthy.

“This study continues to enhance our growing portfolio of published articles demonstrating the viability and benefits of our product offering,” said Dr. Dolev Rafaeli, STRATA’s President and CEO. “This latest study in JCAD is important validation for our TheraClear®X system, and we look forward to sharing it with practitioners and potential customers.”

TheraClear®X is an FDA-cleared, noninvasive device designed to treat mild-to-moderate acne. It combines a gentle vacuum with pulsed broadband light. This combination pulls the skin’s dermal structures toward the surface and removes follicle contents. The broadband light activates porphyrins, which destroy acne-causing bacteria and reduce sebum production. The treatment requires no pre-medication or anesthesia and has no downtime.

The clinical study yielded several key findings:

  • Significant reduction in acne lesion counts at each visit compared to baseline.
  • A ≥1 grade reduction in Investigator’s Global Assessment (IGA) for two-thirds of participants by Day 49.
  • Visible improvements after just three treatments.
  • Consistent enhancements in patient Acne Quality of Life and satisfaction scores.
  • Well-tolerated treatments with no adverse events.
  • High satisfaction, with 80% of participants reporting being satisfied or very satisfied with the treatment.
  • Strong willingness to recommend, with 87% likely to suggest TheraClear®X to a friend.
READ:  Johnson & Johnson Seeks FDA Approval for TREMFYA in Treating Crohn's Disease

Dr. Ablon emphasized the importance of these findings. “The data clearly demonstrates TheraClear®X’s efficacy and safety, providing a significant improvement for acne patients. Noninvasive devices are always needed in the acne armamentarium!”

Revolutionizing Acne Treatment: TheraClear®X Leads the Way

For the general public, this new treatment offers hope for those struggling with acne, particularly when other options have failed or caused undesirable side effects. The high satisfaction rates and lack of adverse events make TheraClear®X a compelling alternative.

This study adds to a growing body of evidence supporting noninvasive acne treatments. Given the high prevalence of acne, especially among adolescents and young adults, effective and comfortable solutions like TheraClear®X could significantly improve quality of life for many.

The implications extend beyond individual treatment. If widely adopted, such devices could shift the paradigm in acne management. They offer dermatologists more tools to tailor treatments to individual needs, potentially leading to better outcomes and higher patient satisfaction.

As STRATA Skin Sciences continues to innovate, the positive results from this study could pave the way for broader acceptance and utilization of photopneumatic therapy in acne treatment.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.